Diagnostic proteomic profile of urine from patients with diabetic nephropathy stage I in diabetes mellitus type 2
Abstract
INTRODUCTION. The epidemiology of diabetic nephropathy (DN) in type 2 diabetes mellitus (DM) is investigated insufficiently since precisely extremely difficult to determine the time of the DN beginning. THE AIM: to search of molecular prognostic markers of DN 1 stage in patients with type 2 DM. PATIENTS AND METHODS. We have verified DN 1 stage patients with type 2 DM (n=42) in study. Control group included 30 healthy persons. The duration of DM was 5,6 years. At the stage of data collection and screening are applied standard methods of DN identification. Qualitative and quantitative molecular phenotyping of urine processed with methods in proteomics (MALDI-TOF-MS/MS, Ultraflex II, «Bruker», USA). The data of the molecular interactions were received with STRING 10.0 database. Statistical analysis was performed using the software “Statistica 12.0” (Statsoft, Russia). RESULTS. We identified potentially new biomarkers of DN 1 stage which could be used to create a noninvasive, urine-based diagnostic tests. The research of signaling pathways and the molecules that influence expression, secretion and amassing of extracellular matrix may aid in strategies for the prophylaxis of DN
About the Authors
V. M. Ibragimov
Dagestan State Medical Academy
Russian Federation
Russian Federation
A. M. Aliskandiev
Dagestan State Medical Academy
Russian Federation
Russian Federation
M. M. Batiushin
Rostov State Medical University
Russian Federation
Russian Federation
I. V. Sarvilina
Medical Centre “Novomeditsina”
Russian Federation
Russian Federation
References
1. International Diabetes Federation, Diabetes Atlas Fifth Edition, International Diabets Federation, Brussels, Belgium, ISSN 1561-6274. Нефрология. 2016. Том 20. №5
2. Шестакова MВ, Шамхалова MШ. Диабетическая нефропатия: клиника, диагностика, терапия / Под ред. ИИ Дедова М., 2009: 27
3. Смирнов АВ, Добронравов ВА, Кисина ААидр. Клинические рекомендации по диагностике и лечению диабетической нефропатии. Нефрология 2015; 19(1): 67-77
4. Shlipak M. Diabetic nephropathy. BMJ Clin Evid 2009; 06.06.
5. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012; 60(5):850-886
6. Smulders X Slaats E, Rakic M et al. Short-term variability and sampling distribution of various parameters of urinary albumin excretion in patients with non-insulin-dependent diabetes mellitus. J Lab Clin Med 1998;132:39-46
7. T. Fiseha Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients. Biomark Res 2015; 3:16-21
8. Alkhalaf A, Zurbig P, Bakker S et al. For the PREDICTIONS Group «Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy». PLoS ONE 2010; 5(10):13421
9. Гасанов МЗ, Батюшин ММ, Терентьев ВП, Садовничая НА. Протеомное исследование мочи у пациентов с гломеурлонефритом и раком почки. Нефрология 2013;5:75-82 [Gasanov MZ, Batiushin MM, Terent'ev VP, Sadovnichaia NA. Proteomnoe issledovanie mochi u patcientov s glomeurlonefritom i rakom pochki. Nefrologiia 2013;5:75-82]
10. Haneda M, Utsunomiya K, Koya D et al. Joint Committee on Diabetic Nephropathy. A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. J. Diabetes Investig 2015; 6(2):242-246
11. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26 (3):725-731
12. Yamazaki M, Ito S, Usami A et al. Urinary excretion rate of ceruloplasmin in non-insulin-dependent diabetic patients with different stages of nephropathy. Eur J Endocrinol 1995; 132: 681-687
13. Randers E, Erlandsen E, Pedersen O et al. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol 2000; 54:203-209
14. Kim S, Song S, Kim I, Jeon Y Urinary Cystatin C and Tubular Proteinuria Predict Progression of Diabetic Nephropathy. Diabetes Care 2013; 36(3): 656-661
15. Miyazono K. TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev 2000; 11(1-2):15-22
16. Shaker O, Sadik N. Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy. Hum Exp Toxicol 2013; 32(10):1089-1096
17. Kolset S, Reinholt F, Jenssen T. Diabetic Nephropathy and Extracellular Matrix. J Histochem Cytochem 2012; 60(12): 976-986
Review
For citations:
Ibragimov V.M., Aliskandiev A.M., Batiushin M.M., Sarvilina I.V. Diagnostic proteomic profile of urine from patients with diabetic nephropathy stage I in diabetes mellitus type 2. Nephrology (Saint-Petersburg). 2016;20(5):69-74. (In Russ.)
Views:
815
Email this article 